Evidence map›Paper›PMID 38206848›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2024

Azaphosphinate Dyes: A Low Molecular Weight Near-Infrared Scaffold for Development of Photoacoustic or Fluorescence Imaging Probes.

Ruwen Yin, Frederik Brøndsted, Lin Li, Julia L McAfee, Yuan Fang, Joshua S Sykes, Yuchen He, Steven Grant, Jiang He, Cliff I Stains

Open access · bronzeAbstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Synthesis of azulene fluorophores reveals structure-property relationships.Organic chemistry frontiers : an international journal of organic chemistry · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Ruwen YinDepartment of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.
Frederik BrøndstedDepartment of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.
Lin LiDivision of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
Julia L McAfeeDepartment of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.
Yuan FangDepartment of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.ORCID https://orcid.org/0000-0003-1987-0885
Joshua S SykesDepartment of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.
Yuchen HeDepartment of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.
Steven GrantDivision of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
Jiang HeDepartment of Radioalogy and Medical Imaging, University of Virginia, Charlottesville, VA 22903, USA.
Cliff I StainsDepartment of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.ORCID https://orcid.org/0000-0002-3165-4539
University of Virginia · USVirginia Commonwealth University · USUniversity of Virginia Medical Center · USVirginia BioTechnology Research Park · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0M
Princess Margaret Phase I Consorium (PMP1C)UM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney · 2014 to 2026
$16.6M
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancerR01CA223767 · NCI · UNIVERSITY OF VIRGINIA · PI HE, JIANG, LIU, BIN · 2018 to 2022
$2.8M
Chemical Approaches for Interrogating Fundamental Biomedical ProcessesR35GM148221 · NIGMS · UNIVERSITY OF VIRGINIA · PI Cliff I Stains · 2023 to 2026
$1.6M
Tunable White Light Laser Confocal/Spectral Imaging MicroscopyS10RR025616 · NCRR · UNIVERSITY OF VIRGINIA · PI PERIASAMY, AMMASI · 2009 to 2009
$500k
NCI NIH HHS P30 CA016059NCI NIH HHS P30 CA044579NCI NIH HHS P30CA044579NCI NIH HHS P30CA16059NCI NIH HHS R01 CA223767NCI NIH HHS R01CA223767NCI NIH HHS UM1 CA186644NCI NIH HHS UM1CA186644NCRR NIH HHS S10 RR025616NIGMS NIH HHS R35 GM148221NIGMS NIH HHS R35GM148221
6 · The paper itself

Abstract

Near-infrared (NIR) dyes are desirable for biological imaging applications including photoacoustic (PA) and fluorescence imaging. Nonetheless, current NIR dyes are often plagued by relatively large molecular weights, poor water solubility, and limited photostability. Herein, we provide the first examples of azaphosphinate dyes which display desirable properties such as low molecular weight, absorption/emission above 750 nm, and remarkable water solubility. In PA imaging, an azaphosphinate dye exhibited a 4.1-fold enhancement in intensity compared to commonly used standards, the ability to multiplex with existing dyes in whole blood, imaging depths of 2.75 cm in a tissue model, and contrast in mice. An improved derivative for fluorescence imaging displayed a >10-fold reduction in photobleaching in water compared to the FDA-approved indocyanine green dye and could be visualized in mice. This new dye class provides a robust scaffold for the development of photoacoustic or NIR fluorescence imaging agents.

Indexed as

Fluorescent DyesIndocyanine GreenAnimalsMiceMolecular WeightOptical ImagingWaterFluorescent DyesIndocyanine GreenWaterFluorescenceFluorescent probesImaging agentsNear-Infrared dyesPhotoacoustic probes

Identifiers

PMID38206848
PMCPMC10957303
OpenAlexW4390754497

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.